Fig. 1.
Descriptive clinical summary of response rates and AOE rates by ponatinib starting dose in the OPTIC trial (adapted from [8]). TE-AOE, treatment-emergent arterial occlusive events.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.